Biotech Values

[DewDiligence]

Feuerstein is an attention-grabbing reporter, but he’s not exactly trustworthy. In 2002, he implied that the only reason IMCL was testing Erbitux in combination with chemotherapy was to exploit the patent on combo use (the one that, ironically, IMCL ended up losing in the Yeda lawsuit). Feuerstein brushed aside the fact that all preclinical data on the EGFR class strongly suggested that combining the drug with chemo was the way to go.

And let’s not forget Feuerstein’s recent botch re Satraplatin (#msg-17912812).

Take Feuerstein with a grain of salt. He is not the devil incarnate, as some investors assert. Nor is he some kind of mad biotech genius.